Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$55.8M Buy
418,657
+160,000
+62% +$18.1M 0.13% 191
2026
Q1
$28.8M Hold
258,657
0.07% 238
2025
Q4
$34.9M Sell
258,657
-202,644
-44% -$22.1M 0.07% 246
2025
Q3
$39.2M Buy
+461,301
New +$28.3M 0.09% 205

Other funds holding ABVX

Holocene Advisors's ABVX Position: Q2 2026 in Review

Holocene Advisors increased its Abivax (ABVX) stake by 62% in Q2 2026, buying an estimated $18.1M and bringing the position to 418,657 shares worth $55.8M. The position accounts for 0.13% of the portfolio, ranked #191.

Holocene Advisors first reported a position in ABVX in Q3 2025 and has held it in 4 quarters since. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Holocene Advisors held 418,657 shares of Abivax worth $55.8M as of Q2 2026.
  • Holocene Advisors bought 160,000 Abivax shares in Q2 2026, an estimated $18.1M.
  • Abivax made up 0.13% of Holocene Advisors's portfolio in Q2 2026, its #191 holding.
  • Holocene Advisors first reported a position in Abivax in Q3 2025 and has held it in 4 quarters since.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.